<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Penn AM</submitter><funding>Alberta Innovates</funding><funding>Genome British Columbia</funding><funding>Genome Canada</funding><pagination>590-599</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6208748</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(6)</volume><pubmed_abstract>A diagnostic blood test for stroke is desirable but will likely require multiple proteins rather than a single "troponin." Validating large protein panels requires large patient numbers. Mass spectrometry (MS) is a cost-effective tool for this task. We compared differences in the abundance of 147 protein markers to distinguish 20 acute cerebrovascular syndrome (ACVS) patients who presented to the Emergency Department of one urban hospital within &lt; 24 h from onset) and from 20 control patients who were enrolled via an outpatient neurology clinic. We targeted proteins from the stroke literature plus cardiovascular markers previously studied in our lab. One hundred forty-one proteins were quantified using MS, 8 were quantified using antibody protein enrichment with MS, and 32 were measured us</pubmed_abstract><journal>Translational stroke research</journal><pubmed_title>Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project.</pubmed_title><pmcid>PMC6208748</pmcid><funding_grant_id>201300690</funding_grant_id><funding_grant_id>TIA-4125</funding_grant_id><pubmed_authors>Trivedi A</pubmed_authors><pubmed_authors>Smith DS</pubmed_authors><pubmed_authors>Coutts SB</pubmed_authors><pubmed_authors>Croteau NS</pubmed_authors><pubmed_authors>Morrison J</pubmed_authors><pubmed_authors>Lam KK</pubmed_authors><pubmed_authors>Lu L</pubmed_authors><pubmed_authors>Borchers CH</pubmed_authors><pubmed_authors>Balshaw RF</pubmed_authors><pubmed_authors>Votova K</pubmed_authors><pubmed_authors>Jackson AM</pubmed_authors><pubmed_authors>Bibok MB</pubmed_authors><pubmed_authors>Penn AM</pubmed_authors><pubmed_authors>Saly V</pubmed_authors><pubmed_authors>Lesperance ML</pubmed_authors></additional><is_claimable>false</is_claimable><name>Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project.</name><description>A diagnostic blood test for stroke is desirable but will likely require multiple proteins rather than a single "troponin." Validating large protein panels requires large patient numbers. Mass spectrometry (MS) is a cost-effective tool for this task. We compared differences in the abundance of 147 protein markers to distinguish 20 acute cerebrovascular syndrome (ACVS) patients who presented to the Emergency Department of one urban hospital within &lt; 24 h from onset) and from 20 control patients who were enrolled via an outpatient neurology clinic. We targeted proteins from the stroke literature plus cardiovascular markers previously studied in our lab. One hundred forty-one proteins were quantified using MS, 8 were quantified using antibody protein enrichment with MS, and 32 were measured us</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Dec</publication><modification>2025-04-04T09:14:50.289Z</modification><creation>2019-03-27T00:06:08Z</creation></dates><accession>S-EPMC6208748</accession><cross_references><pubmed>29368175</pubmed><doi>10.1007/s12975-018-0609-z</doi></cross_references></HashMap>